Be a Pet Health Hero
Help advance a new era of veterinary care by participating in a Gallant clinical trial
Our investigational mesenchymal stromal cell (MSC) therapies are part of a growing movement aimed at restoring health at the source—and clinical studies are how we get there.
Why Stem Cells?
Gallant’s uterine-derived stem cell therapies are built on mesenchymal stromal cells (MSCs) sourced from healthy, FDA-qualified donors. These MSCs are being studied for their ability to target sites of immune dysregulation, modulate inflammatory responses, and restore normal biological function.
Explore our Clinical Trials
Gallant is evaluating investigational MSC therapies intended to address the underlying biology of disease. Each clinical trial is fully funded by Gallant and conducted by trained veterinary professionals at participating clinics.
Clinical Trial participants receive:
- Access to investigational therapy
- Study-related veterinary care (e.g., physical exams, blood work, urinalysis)
- The chance to be a Pet Health Hero by helping Gallant demonstrate the safety and effectiveness of our products for FDA approval
Explore the studies below.
Feline Chronic Gingivostomatitis (FCGS), also known as gingivostomatitis or caudal stomatitis, is a painful and debilitating inflammatory condition affecting the mouth. It can occur in up to 10% of cats, affecting millions of cats in the United States alone.
FCGS causes painful sores in the mouth, which may lead to the following symptoms:
- Reduced appetite
- Weight loss
- Drooling
- Excessive licking
- Reluctance to groom
- Increased vocalization
- Bleeding gums
Treatment for FCGS typically involves removal of some or all of the teeth and daily oral medications to reduce inflammation and pain. Thirty to fifty percent of cats do not improve substantially after these treatments and continue to suffer from chronic pain, a condition known as refractory FCGS.
In refractory FCGS, pain medications and anti-inflammatories may have little effect, and cats may be euthanized due to their poor quality of life. Fortunately, MSC may offer new hope for cats who have exhausted other treatment options.
This study is evaluating MSC therapy for refractory FCGS in cats who have not responded to tooth extraction and medical management.
Feline Osteoarthritis (OA) is a progressive joint disease characterized by joint inflammation and cartilage breakdown. OA affects approximately 90% of older cats and can negatively impact physical appearance, energy and vitality, sociability, and physical and emotional wellbeing.
Clinical signs of Feline OA include:
- Reduced willingness to jump or reduced height of jumping
- Difficulty using stairs
- Slowing down
- Behavior changes including increased sensitivity to touch or handling
- Reduced ability to use the litterbox
- Lameness is more rare
Common treatments including anti-inflammatories and pain medications may not address the underlying progressive disease, and daily medication can stressful for cats and their caregivers.
This study is evaluating MSC therapy for cats with feline osteoarthritis.
Enrollment for this study phase is now complete.
Subscribe to our newsletter for the latest updates on our clinical studies.
Enrollment for this study phase is now complete.
Subscribe to our newsletter for the latest updates on our clinical studies.
Enrollment for this study phase is now complete.
Subscribe to our newsletter for the latest updates on our clinical studies.
